Amisulpride versus Risperidone Treatment for Behavioral and Psychological Symptoms in Patients with Dementia of the Alzheimer Type: A Randomized, Open, Prospective Study

2006 ◽  
Vol 54 (4) ◽  
pp. 247-251 ◽  
Author(s):  
Hyun-Kook Lim ◽  
Chi-Un Pae ◽  
Chul Lee ◽  
Chang-Uk Lee
Keyword(s):  
Prospective Study ◽  
Psychological Symptoms ◽  
Type A ◽  
Alzheimer Type ◽  
Open Prospective Study ◽  
Behavioral And Psychological Symptoms ◽  
Risperidone Treatment

scholarly journals Correlation between Behavioural and Psychological Symptoms of Alzheimer Type Dementia and Plasma Homocysteine Concentration

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Zhanjie Zheng ◽  
Jindong Wang ◽  
Lei Yi ◽  
Hui Yu ◽  
Lingli Kong ◽  
...  
Keyword(s):  
Psychological Symptoms ◽  
Plasma Homocysteine ◽  
Healthy Controls ◽  
Alzheimer Type ◽  
Homocysteine Concentration ◽  
Alzheimer Type Dementia ◽  
Plasma Homocysteine Concentration ◽  
First Time ◽  
The Relationship ◽  
Behavioral And Psychological Symptoms

The relationship between plasma homocysteine and behavioral and psychological symptoms of dementia (BPSD) has not been specifically investigated in previous research. In this study, we compared plasma homocysteine (Hcy) among 40 Alzheimer’s disease (AD) patients with BPSD, 37 AD patients without BPSD, and 39 healthy controls. Our results evidenced that the plasma homocysteine levels in AD patients with BPSD and without BPSD were higher than healthy controls and that the plasma homocysteine concentration in AD patients with BPSD was the highest among the three groups. Significant correlation between plasma homocysteine concentration and cognitive decline and duration of dementia was observed, but there was no correlation between BPSD and cognitive dysfunction or duration of dementia. In conclusion, this study showed for the first time that BPSD were associated with plasma homocysteine concentration in Alzheimer's dementia, and the results supported that hyperhomocysteine may take part in the pathogenesis of BPSD.

scholarly journals Adverse Drug Events in Patients with Dementia and Neuropsychiatric/Behavioral, and Psychological Symptoms, a One-Year Prospective Study

2019 ◽  
Vol 16 (6) ◽  
pp. 934 ◽  
Author(s):  
Marta Hernández ◽  
Conxita Mestres ◽  
Pilar Modamio ◽  
Jaume Junyent ◽  
Lluís Costa-Tutusaus ◽  
...  
Keyword(s):  
Cognitive Impairment ◽  
Prospective Study ◽  
Adverse Drug Events ◽  
Psychological Symptoms ◽  
Functional Dependence ◽  
Interdisciplinary Teams ◽  
Naranjo Algorithm ◽  
One Year ◽  
Reduced Mobility ◽  
Behavioral And Psychological Symptoms

Older people usually present with adverse drug events (ADEs) with nonspecific symptoms such as cognitive decline, recurrent falls, reduced mobility, and/or major deterioration. The aims of this study were to assess the ADEs of patients with dementia and presenting neuropsychiatric/behavioral, and psychological symptoms in dementia (BPSD) and to categorize and identify the principal factors that allow to prevent ADEs, and separately ADEs that result in falls. To that end, a one-year prospective study in a psychogeriatric ward (July 2015 to July 2016) was performed. All patients admitted to this ward were eligible for enrolment. Patients who met any of the following criteria were excluded from the study: Patients without cognitive impairment, a length of stay under 7 days, and palliative or previous psychiatric pathology. We included 65 patients (60% women, 84.9 years ± 6.7) with mild to moderate cognitive impairment, moderate to severe functional dependence, and a high prevalence of geriatric syndromes and comorbidity. A total of 87.7% were taking five or more drugs (mean 9.0 ± 3.1). ADEs were identified during the interdisciplinary meeting and the follow up by clinical record. Sixty-eight ADEs (81.5% patients) were identified, of which 73.5% were not related to falls. From these, 80% were related to drugs of the nervous system. The Naranjo algorithm determined that 90% of ADEs were probable. The severity of the ADEs was Category E in 34 patients (68%). The number of preventable ADE according to the Schumork–Thornton test was 58%. The main ADE was drowsiness/somnolence (27.7%). ADEs related to falls represented a 26.5%. The balance between effective treatment and safety is complex in these patients. A medication review in interdisciplinary teams is an essential component to optimize safety prevention.

Quetiapine Treatment for Behavioral and Psychological Symptoms in Patients with Senile Dementia of Alzheimer Type

2004 ◽  
Vol 49 (4) ◽  
pp. 201-204 ◽  
Author(s):  
Tokumi Fujikawa ◽  
Terumichi Takahashi ◽  
Akiko Kinoshita ◽  
Hiroaki Kajiyama ◽  
Akiko Kurata ◽  
...  
Keyword(s):  
Psychological Symptoms ◽  
Senile Dementia ◽  
Alzheimer Type ◽  
Dementia Of Alzheimer Type ◽  
Behavioral And Psychological Symptoms

Does Personality Predict Behavioral and Psychological Symptoms of Dementia? Results from PACO Prospective Study

2019 ◽  
Vol 69 (4) ◽  
pp. 1099-1108 ◽  
Author(s):  
Isabelle Rouch ◽  
Jean-Michel Dorey ◽  
Catherine Padovan ◽  
Béatrice Trombert-Paviot ◽  
Michel Benoit ◽  
...  
Keyword(s):  
Prospective Study ◽  
Psychological Symptoms ◽  
Behavioral And Psychological Symptoms

Evaluation of risperidone in the treatment of behavioral and psychological symptoms and sleep disturbances associated with dementia

2005 ◽  
Vol 17 (4) ◽  
pp. 591-604 ◽  
Author(s):  
J. C. Durán ◽  
A. Greenspan ◽  
J. I. Diago ◽  
R. Gallego ◽  
G. Martinez
Keyword(s):  
Adverse Events ◽  
Sleep Disturbances ◽  
Psychological Symptoms ◽  
Neuropsychiatric Inventory ◽  
Open Label ◽  
Sleep Behavior ◽  
The Mean ◽  
Behavioral And Psychological Symptoms ◽  
Progressive Cognitive Impairment ◽  
Risperidone Treatment

Background: Dementia is associated with progressive cognitive impairment and behavioral and psychological symptoms. Sleep–wake cycle disturbances are common in patients with dementia. This study evaluated the efficacy and safety of risperidone in the treatment of the behavioral and psychological symptoms of dementia (BPSD) and associated sleep–wake cycle disturbances.Methods: In this open-label, 12-week, observational, prospective study, the effects of risperidone were assessed using the Neuropsychiatric Inventory (NPI) total and subscale scores. Sleep–wake cycle disturbances were rated by patients/caregivers using a newly developed sleep behavior questionnaire that included assessment of sleep duration, quality, awakenings, and effects on daily activities. Tolerability assessments included the Udvalg for Kliniske Undersogelser (UKU) subscale for extrapyramidal symptoms (EPS) and the recording of adverse events.Results:A total of 338 patients entered the study, with 321 patients completing. Following 12 weeks of risperidone treatment (mean dose 1.49 mg/day at end-point), the mean NPI score was reduced to 10.6 from a baseline score of 28.7. Compared with baseline, patients/caregivers reported significant improvements following 12 weeks of risperidone in total sleep hours at night (5.5 vs. 7.1 hours), hours awake in bed at night (2.3 vs. 1.2 hours), insomnia (40.1% vs. 8.4%), and other sleep-related variables. Six patients reported a total of 10 adverse events, including somnolence (n = 3) and sialorrhea (n = 2). Scores on the UKU subscale of EPS improved significantly (mean 4.0 at baseline vs. 1.7 at week 12).Conclusions: Risperidone is effective and well tolerated in the treatment of BPSD and associated sleep disturbances.

Sign in / Sign up

Export Citation Format

Share Document